Brook, M., Hennessy, C., Hester, J., Hammad, S., Alzhrani, A., Rombach, I., . . . Issa, F. (2024). Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation. Wolters Kluwer.
Citación estilo ChicagoBrook, MO, et al. Late Treatment with Autologous Expanded Regulatory T-cell Therapy After Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation. Wolters Kluwer, 2024.
Cita MLABrook, MO, et al. Late Treatment with Autologous Expanded Regulatory T-cell Therapy After Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation. Wolters Kluwer, 2024.